Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

Publish date: June 27, 2018

 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Pages

Recommended Reading

FDA approves IL-23 antagonist for plaque psoriasis
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Rheumatology
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Rheumatology
New PsA questionnaire fails to beat existing early screening methods
MDedge Rheumatology
How to avoid severe diarrhea from apremilast
MDedge Rheumatology
Is PASI 100 the new benchmark in psoriasis?
MDedge Rheumatology
Psoriasis duration reflects cardiovascular event risk
MDedge Rheumatology
CBC values linked to CVD risk in psoriasis
MDedge Rheumatology
Psoriasis therapy with biologics not linked to increased cancer risk
MDedge Rheumatology